Topical use of Levofloxacin for reducing lung inflammation
First Claim
Patent Images
1. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml.
7 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.
-
Citations
47 Claims
- 1. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml.
- 34. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject, wherein the pulmonary inflammation is induced by one or more pro-inflammatory cytokines, said method comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a reduction in the pulmonary concentration of said cytokine by at least 10%, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml.
-
39. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a reduction in the pulmonary concentration of one or more pro-inflammatory cytokines selected from IL-1β
- , IL-6 and IL-8, whereby the pulmonary inflammation is reduced or suppressed, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml.
- View Dependent Claims (40, 41, 42)
-
43. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject, wherein the pulmonary inflammation is induced by one or more mediators selected from TNFα
- and LPS, said method comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml.
- 44. A method for reducing the pulmonary concentration of one or more pro-inflammatory cytokine in the absence of a pulmonary bacterial infection in a subject, said method comprising administering to said subject in need thereof an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation, wherein the solution comprises a divalent or trivalent cation concentration from about 150 mM to about 250 mM, and a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 125 mg/ml.
Specification